Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivipansel PK and Safety in Young vs Elderly Healthy Volunteers
NCT02998099Phase 1Completed
- Sponsor
- GlycoMimetics
- Start
- Jan 2017
- Primary completion
- Feb 2017
- Modality
- Bivalent/Multivalent Binders, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivipansel in sickle cell disease (SCD) (2 arms), sponsored by GlycoMimetics. Primary endpoints: Area under the plasma concentration-time profile from time 0 extrapolated to infinite time at 72 hours and Clearance at 72 hours. Started Jan 2017; status: completed.
02
Drugs
rivipansel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02998099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998099.